Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IL-17: Pushing The Limits Of A Drug Target

This article was originally published in Start Up

Executive Summary

A series of recent and anticipated events is drawing attention to interleukin-17 and related cytokines – a set of immunological drug targets of long-standing interest to large and small companies. The current crop of big-company candidates are biologics and may prove too harsh for all but the most severe immunological conditions, leaving room for start-ups developing small molecules.

Advertisement

Related Content

Novartis Targets Leading MS Role With Gilenya, BAF312 And IL-17 Pathway
Lilly’s Ixekizumab Results More Than Skin Deep In Psoriasis Study
Secukinumab Phase III Data Look Reassuring Ahead Of Advisory Committee Review
Secukinumab Phase III Data Look Reassuring Ahead Of Advisory Committee Review
Merck’s Big Move: Massive Cost Cuts And R&D Changes Ahead
Putting The Brakes On The Immune Response
After The Anti-TNFs, What’s Next In Autoimmune Disease?
Psoriasis Market Snapshot: An Area Drug Makers Are Itching To Get Into
Novartis Ilaris Approved For Rare Autoinflammatory Disorder; Filings For More Common Diseases Planned
The Epigenetics (R)evolution

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092522

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel